Alnylam Pharmaceuticals (ALNY)
Sector: | Health Care |
Super Investor Stats: | |
Ownership count: | 1 |
Ownership rank: | 667 |
% of all portfolios: | 0.007% |
History | Portfolio Manager | Activity ▲ | Share change | % change to portfolio | |
Q3  2023 | |||||
≡ | Dodge & Cox | Add 0.50% | 12,000 | 0.00 | |
Q4  2021 | |||||
≡ | Dodge & Cox | Add 4.50% | 140,000 | 0.02 | |
Q2  2021 | |||||
≡ | Dodge & Cox | Add 28.40% | 687,685 | 0.13 | |
Q4  2020 | |||||
≡ | Lee Ainslie - Maverick Capital | Add 1.76% | 17,041 | 0.04 | |
Q1  2020 | |||||
≡ | First Eagle Investment Management | Buy | 26,500 | 0.01 | |
Q2  2019 | |||||
≡ | Dodge & Cox | Add 6.32% | 190,000 | 0.02 | |
≡ | Lee Ainslie - Maverick Capital | Add 31.95% | 1,025,629 | 1.08 | |
Q1  2019 | |||||
≡ | Dodge & Cox | Add 6.89% | 193,900 | 0.03 | |
≡ | Lee Ainslie - Maverick Capital | Add 14.50% | 406,436 | 0.50 | |
Q4  2018 | |||||
≡ | Lee Ainslie - Maverick Capital | Add 85.44% | 1,291,887 | 1.38 | |
Q3  2018 | |||||
≡ | Lee Ainslie - Maverick Capital | Add 121.92% | 830,710 | 0.91 | |
Q2  2018 | |||||
≡ | Lee Ainslie - Maverick Capital | Buy | 681,354 | 0.78 | |
Q1  2017 | |||||
≡ | Dodge & Cox | Add 1.29% | 70,000 | 0.01 | |
Q4  2016 | |||||
≡ | Dodge & Cox | Add 63.44% | 2,107,967 | 0.13 | |
Q3  2016 | |||||
≡ | Dodge & Cox | Add 100.01% | 1,661,438 | 0.20 | |
Q2  2016 | |||||
≡ | Dodge & Cox | Buy | 1,661,330 | 0.17 | |
Q1  2013 | |||||
≡ | Thomas Russo - Gardner Russo & Quinn | Buy | 75 | 0.00 |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.